For many years, psoriatic arthritis (PsA) treatment was the poor little brother of rheumatoid arthritis (RA) therapeutics. The older brother would get new clothes and shoes almost every year, but the younger child would have to be content with hand-me-downs.
Likewise, for RA, novel antirheumatic agents were developed in large clinical trial programs at a breakneck pace. But only once their efficacy was formally established in RA, and usually after the drug had been brought to market, did clinical trial programs in PsA get under way—seemingly as an afterthought. And indeed, many of the conventional and biologic disease-modifying antirheumatic drugs (DMARDs) that were approved for RA demonstrated efficacy in PsA as well and received formal approval. But again, this was usually after several years’ delay.